The EID3 Knockout HeLa Polyclonal Cells constitute a ready-to-use CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HeLa cervical adenocarcinoma cell line, engineered for loss-of-function studies of the EID3 transcriptional co-repressor. This polyclonal pool provides a heterogeneous gene-disrupted model suitable for population-based functional assays while avoiding clonal selection biases.
The parental HeLa cell line, an HPV18-immortalized cervical adenocarcinoma epithelial model, is a mainstay of cancer and cell biology research owing to its robust growth and well-characterized signaling networks. Its well-documented genetic background, including partial inactivation of p53 and Rb tumor suppressors by viral oncoproteins, makes it particularly relevant for dissecting molecular pathways implicated in HPV-driven carcinogenesis and enables straightforward comparisons with extensive published data.
EID3 functions as a transcriptional co-repressor by directly binding to the histone acetyltransferases EP300 and CREBBP, thereby inhibiting their enzymatic activity. This suppression attenuates EP300/CREBBP-dependent acetylation of histones and transcription factors, leading to reduced transactivation of critical p53-responsive genes including CDKN1A (p21) and BAX. Consequently, EID3 dampens p53-mediated cell cycle arrest and apoptosis. EID3 expression is modulated by upstream TGF-beta signaling via SMAD2/SMAD3 transcriptional complexes and can be transcriptionally regulated by p53 itself, positioning EID3 within feedback loops controlling growth inhibition and survival. Through EP300/CREBBP, EID3 also indirectly affects Notch and cell cycle pathways, integrating signals that control proliferation and differentiation.
In the HeLa background, where HPV18 E6/E7 oncoproteins partially impair p53 and retinoblastoma tumor suppressor functions, EID3 disruption is expected to relieve the inhibition of EP300/CREBBP, potentially restoring histone acetylation and p53-dependent transcriptional programs. This model is therefore valuable for dissecting how EID3 modulates p53 and TGF-beta signaling outputs in cervical adenocarcinoma cells, offering insights into epigenetic mechanisms that govern cell cycle arrest and apoptosis in an HPV-immortalized context.
These polyclonal EID3 knockout cells are ideally suited for investigating EID3-dependent transcriptional repression in cervical cancer and for probing the interplay between oncogenic HPV proteins and host epigenetic regulators. Researchers can employ them in western blotting and RT-qPCR analyses to assess changes in CDKN1A, BAX, and other p53 targets, or in ChIP-qPCR to measure histone acetylation at target gene promoters. Co-immunoprecipitation and reporter assays enable direct interrogation of EID3’s binding to EP300 and CREBBP and its impact on transcriptional activity. Flow cytometry and drug sensitivity assays facilitate the study of cell cycle perturbations and apoptotic responses upon chemotherapeutic treatment. For further technical details or to discuss custom applications, please contact Ascent Research.
